Home » Stocks » IMAB

I-Mab (IMAB)

Stock Price: $62.07 USD 3.31 (5.63%)
Updated May 12, 2021 4:00 PM EDT - Market closed
After-hours: $62.50 +0.43 (0.69%) May 12, 7:08 PM
Market Cap 4.38B
Revenue (ttm) 235.88M
Net Income (ttm) 72.01M
Shares Out 72.41M
EPS (ttm) 4.59
PE Ratio 13.53
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 12
Last Price $62.07
Previous Close $58.76
Change ($) 3.31
Change (%) 5.63%
Day's Open 58.71
Day's Range 58.71 - 62.13
Day's Volume 651,122
52-Week Range 17.86 - 65.94

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

As the market gets back to normal, it's a great time to explore the pharma stocks that got lost in the vaccine frenzy of the past year. The post 7 of the Best Pharma Stocks to Buy Now appeared first on ...

Other stocks mentioned: ALLK, HZNP, IBRX, MNMD, SAGE, SWTX
1 day ago - InvestorPlace

SHANGHAI and GAITHERSBURG, Md., April 29, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercializat...

1 week ago - PRNewsWire

SHANGHAI and GAITHERSBURG, Md., April 28, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercializat...

2 weeks ago - PRNewsWire

I-Mab (NASDAQ: IMAB) has announced topline results from its Phase 2 study evaluating olamkicept (also known as TJ301) in patients with active ulcerative colitis (UC). The study met its primary endpoint ...

2 weeks ago - Benzinga

SHANGHAI and GAITHERSBURG, Md., April 26, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercializat...

2 weeks ago - PRNewsWire

SHANGHAI, China., and GAITHERSBURG, MD, April 14, 2021 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and co...

4 weeks ago - GlobeNewsWire

SHANGHAI, China and GAITHERSBURG, Md., March 31, 2021 (GLOBE NEWSWIRE) -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and com...

1 month ago - GlobeNewsWire

SHANGHAI, China and GAITHERSBURG, Md., March 30, 2021 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the development of novel biologics...

1 month ago - GlobeNewsWire

SHANGHAI, China and GAITHERSBURG, Md., March 29, 2021 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and com...

1 month ago - GlobeNewsWire

Mandarin session on April 7, 2021 and English session on April 26, 2021 for investors and research analysts

1 month ago - GlobeNewsWire

SHANGHAI, China and GAITHERSBURG, Md., March 19, 2021 (GLOBE NEWSWIRE) -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and com...

1 month ago - GlobeNewsWire

Shares of the U.S.-listed Chinese immuno-oncology company I-Mab (NASDAQ: IMAB) offer strong upside potential, according to a Needham analyst.  The I-Mab Analyst: Chad Messer initiated coverage of I-Mab ...

1 month ago - Benzinga

- New Initiative is part of I-Mab's long-term strategy to drive innovation and scientific leadership in immuno-oncology - New collaborations signed will allow I-Mab access to cutting edge technology pla...

2 months ago - GlobeNewsWire

SHANGHAI and GAITHERSBURG, Md., Feb. 5, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializatio...

3 months ago - PRNewsWire

SHANGHAI and GAITHERSBURG, Md., Feb. 5, 2021 /PRNewswire/ -- I-Mab (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or hi...

3 months ago - PRNewsWire

SHANGHAI and GAITHERSBURG, Md., Feb. 4, 2021 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializatio...

3 months ago - PRNewsWire

SHANGHAI, China and PLANEGG/MUNICH, Germany, Jan. 25, 2021 /PRNewswire/ -- I-Mab (Nasdaq: IMAB), and MorphoSys (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) today announced that the fir...

3 months ago - PRNewsWire

SHANGHAI and GAITHERSBURG, Md., Dec. 23, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializati...

4 months ago - PRNewsWire

SHANGHAI and GAITHERSBURG, Md., Dec. 4, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializatio...

5 months ago - PRNewsWire

SHANGHAI and GAITHERSBURG, Md., Dec. 1, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializatio...

5 months ago - PRNewsWire

SHANGHAI and GAITHERSBURG, Md., Dec. 1, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializatio...

5 months ago - PRNewsWire

In a GuruFocus article on Nov. 17, I took a look at three of the nine public Chinese biotechnology companies that are projected to become major international competitors in the coming years, according t...

Other stocks mentioned: IVBXF
5 months ago - GuruFocus

Innoforce, a Hangzhou company, formed a JV with Thermo Fisher Scientific to build a large biologics and steriles drug development and manufacturing facility in the Hangzhou Airport Economic Demonstratio...

Other stocks mentioned: BGNE, BNTX, CALT, MRK, PFE, TMO
5 months ago - Seeking Alpha

SHANGHAI and GAITHERSBURG, Md., Nov. 13, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializati...

5 months ago - PRNewsWire

SHANGHAI and GAITHERSBURG, Md., Nov. 11, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializati...

6 months ago - PRNewsWire

SHANGHAI and GAITHERSBURG, Md., Nov. 9, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializatio...

6 months ago - PRNewsWire

SHANGHAI, China, and GAITHERSBURG, MD., Oct. 28, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commerc...

6 months ago - PRNewsWire

SHANGHAI and GAITHERSBURG, Md., Oct. 27, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializati...

6 months ago - PRNewsWire

PLANEGG/MUNICH, Germany and SHANGHAI, China, Sept. 17, 2020 /PRNewswire/ -- MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and I-Mab (Nasdaq: IMAB) today jointly announced t...

7 months ago - PRNewsWire

I-Mab (IMAB) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

8 months ago - Zacks Investment Research

Companies in the news are: IMAB, LMPX, DPW, ANPC

Other stocks mentioned: ANPC, DPW
8 months ago - Zacks Investment Research

Shanghai's I-Mab out-licensed ex-China rights for lemzoparlimab, its anti-CD47 mAb, to AbbVie in a blockbuster $2 billion agreement.

Other stocks mentioned: ABBV
8 months ago - Seeking Alpha

I-Mab (IMAB) is seeing gains to IMAB stock on Friday after the biopharma company announced news of a deal with AbbVie (ABBV).

8 months ago - InvestorPlace

The deal could be the largest-ever out-licensing agreement by a Chinese biotech.

Other stocks mentioned: ABBV
8 months ago - The Motley Fool

Shares of I-Mab IMAB, +0.47% soared 17% in premarket trading Friday toward a record high, after the China-based biotechnology company announced a collaboration agreement with AbbVie Inc.

8 months ago - Market Watch

SHANGHAI and GAITHERSBURG, Md., Sept. 4, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializati...

8 months ago - PRNewsWire

Shares of Chinese biopharmaceutical company I-Mab (NASDAQ:IMAB) continued to impress following the recent half-year results for the period ended June 30.

8 months ago - GuruFocus

I-Mab's (IMAB) CEO Joan Huaqiong Shen on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Positive preliminary clinical trial results for lemzoparlimab (TJC4) demonstrate a differentiated drug profile in safety and pharmacokinetics in cancer patients Joined the global effort against COVID-19...

8 months ago - PRNewsWire

SHANGHAI and GAITHERSBERG, Md., Aug. 17, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializati...

8 months ago - PRNewsWire

SHANGHAI and GAITHERSBERG, Md., Aug. 4, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializatio...

9 months ago - PRNewsWire

SHANGHAI and GAITHERSBERG, Md., July 28, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializati...

9 months ago - PRNewsWire

SHANGHAI and GAITHERSBURG, Md., July 15, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializati...

9 months ago - PRNewsWire

SHANGHAI and GAITHERSBURG, Md., June 12, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializati...

11 months ago - PRNewsWire

About IMAB

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and O... [Read more...]

Industry
Biotechnology
IPO Date
Jan 17, 2020
Stock Exchange
NASDAQ
Ticker Symbol
IMAB
Full Company Profile

Financial Performance

Financial numbers in millions CNY.
Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for I-Mab stock is "Strong Buy." The 12-month stock price forecast is 77.35, which is an increase of 24.62% from the latest price.

Price Target
$77.35
(24.62% upside)
Analyst Consensus: Strong Buy